Related Experiment Video

Updated: Aug 15, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Bone mineral density changes on androgen deprivation therapy for prostate cancer and response to antiresorptive

S Yaturu1, S DjeDjos, G Alferos

  • 1Department of Endocrinology, Overton Brooks VAMC/LSU HSC, Shreveport, LA 71101-4295, USA. yaturu@yahoo.com

Prostate Cancer and Prostatic Diseases
|November 9, 2005
PubMed

Insights

Androgen deprivation therapy for prostate cancer significantly increases osteoporosis risk. Bone mineral density (BMD) monitoring and antiresorptive therapy are crucial for managing bone loss in these patients.

Area of Science:

  • Oncology
  • Endocrinology
  • Bone Metabolism

Background:

  • Androgen deprivation therapy (ADT) is a cornerstone in prostate cancer treatment.
  • ADT induces a hypogonadal state, a known risk factor for osteoporosis.
  • Skeletal integrity is hormone-dependent, making ADT a concern for bone health.

Purpose of the Study:

  • To investigate the extent of bone loss in prostate cancer patients undergoing ADT.
  • To assess the impact of ADT duration on bone mineral density (BMD).
  • To evaluate the efficacy of antiresorptive therapy in mitigating ADT-induced bone loss.

Main Methods:

  • Retrospective review of BMD studies in 152 prostate cancer patients on ADT (mean duration 58 months).
  • Analysis of follow-up BMD measurements at 12-15 months for 55 patients.
  • Comparison of BMD changes in patients with and without antiresorptive therapy.

Main Results:

  • Osteoporosis was diagnosed in 60.5% of patients, with hip involvement in 48.7%.
  • Osteopenia was present in 24% of patients; only 11% had normal BMD.
  • Antiresorptive therapy showed significant BMD improvement at 12-15 month follow-up.

Conclusions:

  • Men receiving ADT for prostate cancer are at high risk for significant bone loss.
  • Baseline and periodic BMD measurements are recommended for patients on ADT.
  • Antiresorptive therapy can effectively improve BMD in patients undergoing ADT.

Related Concept Videos

Bone Disorders01:29

Bone Disorders

Aging and its effect on bone remodeling is the most common cause of bone disorders. In young and healthy people, bone deposition and resorption happen at an equal rate to maintain optimal bone health.
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
Bone Remodeling01:40

Bone Remodeling

Bone remodeling is a continuous and balanced process of bone resorption by osteoclasts and bone formation by osteoblasts. In adults, it helps maintain bone mass and calcium homeostasis. While mechanical stress can stimulate turnover as part of the normal maintenance and reparative process, several hormones also regulate bone remodeling.
Osteoclasts in Bone Remodeling01:31

Osteoclasts in Bone Remodeling

Osteoclasts are cells responsible for bone resorption and remodeling. They originate from hematopoietic progenitor cells present in the bone marrow. Numerous progenitor cells fuse to form multinucleated cells, each with 10-20 nuclei. A single osteoclast has a diameter of 150 to 200 µM. These cells have ruffled borders that break down the underlying bone tissue and release minerals such as calcium into the blood in bone resorption. Osteoclasts cling to bones with their ruffled edges during bone...
Hormones and Bone Tissue01:17

Hormones and Bone Tissue

The endocrine system produces and secretes hormones, which interact with the skeletal system. These hormones control bone growth, maintain bone once it is formed, and remodel it.
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
Role of Vitamins in Maintaining Bone Health01:25

Role of Vitamins in Maintaining Bone Health

The growth and maintenance of bone are regulated by a combination of nutritional factors, including vitamins, such as vitamin A, B12, C, D, and K.
Vitamin A
Vitamin A is involved in the process of bone remodeling. Retinoic acid, the active metabolite of Vitamin A, has nuclear receptors in osteoblasts and osteoclasts, which are involved in bone remodeling.
Vitamin B12
Vitamin B12 acts as a cofactor during the formation of osteoblast-related proteins, such as osteocalcin. Vitamin B12 plays a role...